Page last updated: 2024-08-16

temozolomide and nutlin-3a

temozolomide has been researched along with nutlin-3a in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's4 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Kayama, T; Kitanaka, C; Matsuda, K; Sato, A; Seino, S; Sunayama, J; Suzuki, K; Tachibana, K; Tomiyama, A; Watanabe, E1
Bossert, C; Chastagner, P; Dontenwill, M; Entz-Werle, N; Godet, J; Guenot, D; Guerin, E; Janouskova, H; Leger, DY; Lehmann-Che, J; Maglott, A; Martin, S; Noulet, F; Pinel, S; Plenat, F; Teisinger, J1
Bailey, BJ; Bringman, LR; Cai, S; Cai, W; Cohen-Gadol, AA; Ding, J; Eitel, JA; Gelbert, LM; Georgiadis, TM; Gordon, KR; Jones, DR; Long, EC; Mayo, LD; Minto, RE; Murray, ME; Pollok, KE; Reza Saadatzadeh, M; Sarkaria, JN; Sen, SE; Shannon, HE; Tonsing-Carter, E; Wang, H; Waning, DL; Wells, CD; Zachary Gunter, T1
Barone, D; Capone, F; Cirillo, D; Di Marzo, D; Forte, IM; Giordano, A; Iannuzzi, CA; Indovina, P; Pentimalli, F1

Other Studies

4 other study(ies) available for temozolomide and nutlin-3a

ArticleYear
MEK-ERK signaling dictates DNA-repair gene MGMT expression and temozolomide resistance of stem-like glioblastoma cells via the MDM2-p53 axis.
    Stem cells (Dayton, Ohio), 2011, Volume: 29, Issue:12

    Topics: Aminoacetonitrile; Animals; Dacarbazine; DNA Modification Methylases; DNA Repair; DNA Repair Enzymes; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Imidazoles; Male; MAP Kinase Signaling System; Mice; Mice, Inbred BALB C; Piperazines; Proto-Oncogene Proteins c-mdm2; RNA Interference; Temozolomide; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Tumor Suppressor Proteins

2011
Integrin α5β1 plays a critical role in resistance to temozolomide by interfering with the p53 pathway in high-grade glioma.
    Cancer research, 2012, Jul-15, Volume: 72, Issue:14

    Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Glioblastoma; Humans; Imidazoles; Integrin alpha5beta1; Mice; Piperazines; Temozolomide; Treatment Outcome; Tumor Suppressor Protein p53

2012
Combination therapy in a xenograft model of glioblastoma: enhancement of the antitumor activity of temozolomide by an MDM2 antagonist.
    Journal of neurosurgery, 2017, Volume: 126, Issue:2

    Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Disease Models, Animal; Glioblastoma; Humans; Imidazoles; Piperazines; Proto-Oncogene Proteins c-mdm2; Temozolomide; Xenograft Model Antitumor Assays

2017
Targeted therapy based on p53 reactivation reduces both glioblastoma cell growth and resistance to temozolomide.
    International journal of oncology, 2019, Volume: 54, Issue:6

    Topics: Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Furans; Glioblastoma; Humans; Imidazoles; Mutation; Piperazines; Protein Binding; Proto-Oncogene Proteins c-mdm2; Temozolomide; Tumor Suppressor Protein p53

2019